Strategists say Trump's ‘incoherent’ claims undercut his energy message
The GOP nominee has made dubious claims about U.S. oil output, pipelines and Vice President Kamala Harris' plans for fracking ...
Alaska Dispatch News14d
Nearly 2,000 drug plants are overdue for FDA checks after COVID delays
The firms that are overdue for safety and quality inspections represent about 42% of the 4,700 plants that are currently registered to produce drugs for the U.S. and previously underwent FDA ...
NECN14d
Nearly 2,000 drug plants are overdue for FDA checks after COVID delays, AP finds
The firms that are overdue for safety and quality inspections represent about 42% of the 4,700 plants that are currently registered to produce drugs for the U.S. and previously underwent FDA ...
NBC Chicago15d
Nearly 2,000 drug plants are overdue for FDA checks after COVID delays, AP finds
Federal regulators responsible for the safety of the U.S. drug supply are still struggling to get back to where they were in 2019, before the COVID-19 pandemic upended factory inspections in the U ...
The Virginian-Pilot15d
Nearly 2,000 drug manufacturing plants are overdue for FDA inspections after COVID delays, AP finds
The firms that are overdue for safety and quality inspections represent about 42% of the 4,700 plants that are currently registered to produce drugs for the U.S. and previously underwent FDA ...
WRAL15d
Nearly 2,000 drug plants are overdue for FDA checks after COVID delays, AP finds
Most of the overdue plants are in the U.S., but more than 340 are in India and China, countries that together make up the largest source of drug ingredients used in low-cost U.S. prescriptions.
denver715d
Nearly 2,000 drug plants are overdue for FDA checks after COVID delays, AP finds
The firms that are overdue for safety and quality inspections represent about 42% of the 4,700 plants that are currently registered to produce drugs for the U.S. and previously underwent FDA review ...
San Mateo Daily Journal15d
Nearly 2,000 drug plants are overdue for FDA checks after COVID delays, AP finds
WASHINGTON (AP) — Federal regulators responsible for the safety of the U.S. drug supply are still struggling to get back to where they were in 2019, before the COVID-19 pandemic upended factory ...